Mainz BioMed N.V. | Finanzwire

BRIEF

published on 07/25/2024 at 14:06, 1 year 6 months ago

Mainz Biomed Launches Enhanced ColoAlert to Improve Screening Efficiency

ColoAlert Mainz Biomed Colorectal Cancer Screening Efficiency DNA Stabilizing Buffer
PRESS RELEASE

published on 07/25/2024 at 14:01, 1 year 6 months ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed launches enhanced ColoAlert test with new features to improve screening efficiency and user experience. The updates aim to optimize colorectal cancer detection

ColoAlert Mainz Biomed Colorectal Cancer Screening Efficiency Enhanced Test
BRIEF

published on 07/09/2024 at 09:06, 1 year 6 months ago

Mainz Biomed Submits for FDA Breakthrough Device Designation for CRC Screening Test

Mainz Biomed Colorectal Cancer FDA Submission Breakthrough Device Screening Test
PRESS RELEASE

published on 07/09/2024 at 09:01, 1 year 6 months ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed N.V. seeks FDA Breakthrough Device Designation for Next Generation CRC Screening Test with impressive clinical results

Mainz Biomed N.V. Colorectal Cancer MRNA Biomarkers FDA Breakthrough Device Designation Next Generation CRC Screening Test
BRIEF

published on 07/02/2024 at 14:06, 1 year 6 months ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Diagnostic Solutions FDA Approval Mainz Biomed Colorectal Cancer Half Year Results
PRESS RELEASE

published on 07/02/2024 at 14:01, 1 year 6 months ago

Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed N.V. provides corporate update for the first half of 2024, showcasing industry-leading clinical data and strategic partnerships. Expect half-year financial results in September 2024

Strategic Partnerships Corporate Update Clinical Data Mainz Biomed N.V. Half-year Financial Results
BRIEF

published on 06/03/2024 at 14:06, 1 year 7 months ago

Mainz Biomed Unveils Industry-Leading Study Results at ASCO 2024

Mainz Biomed MRNA Biomarkers ASCO 2024 CRC Detection Multimodal Screening
PRESS RELEASE

published on 06/03/2024 at 14:01, 1 year 7 months ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed presented industry-leading results of its pooled study at ASCO 2024, demonstrating high sensitivity in detecting colorectal cancer and precancerous lesions using mRNA biomarkers and AI algorithm

Mainz Biomed Colorectal Cancer MRNA Biomarkers ASCO 2024 Precancerous Lesions
BRIEF

published on 05/28/2024 at 14:06, 1 year 8 months ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data at ASCO 2024

Colorectal Cancer AI Algorithm ASCO 2024 Screening Data
PRESS RELEASE

published on 05/28/2024 at 14:01, 1 year 8 months ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed to present new pooled colorectal cancer screening data at ASCO 2024 Annual Meeting, showcasing significant advancements in early detection and diagnostic performance

Early Detection Mainz Biomed Colorectal Cancer ASCO 2024 Screening Data

Published on 01/30/2026 at 14:00, 2 hours 17 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 42 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 17 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 14 hours 2 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 17 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 16:00, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:59, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/30/2026 at 15:58, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 01/30/2026 at 15:57, 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/30/2026 at 15:56, 20 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

View all EQS

Published on 01/30/2026 at 08:00, 8 hours 17 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 22 hours 17 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 32 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 32 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 22 hours 37 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News